Physician profile
Sally B Escuin
NPI 1417422718
$5,314.23
in general payments reported to CMS, 2019-2025
26 companies · $630 in 2025
The $630 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $1,328 · 2023: $1,706 · 2024: $1,253 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,580.77 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,090.37 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $619.05 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $512.40 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $320.64 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Abbott Laboratories | $300.98 | 2023-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $282.58 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $261.11 | 2023-2025 | |
| Dexcom, INC. | $254.86 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $232.79 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $194.66 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Abbvie INC. | $173.26 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $164.49 | 2022-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $152.54 | 2022 | |
| Pfizer INC. | $119.77 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $104.59 | 2022-2024 | Farxiga |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $95.57 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $94.84 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $74.43 | 2025 | Korlym |
| Halozyme INC | $60.69 | 2023 | |
| Phathom Pharmaceuticals, INC. | $48.15 | 2024-2025 | Voquezna |
| Organon LLC | $32.95 | 2022-2024 | |
| Genentech USA, INC. | $31.98 | 2021-2022 | |
| Amgen INC. | $27.58 | 2024-2025 | Prolia, Evenity, Repatha |
| Amarin Pharma, INC. | $22.96 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.15 | 2022 | |
| Dynavax Technologies Corporation | $19.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Escuin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.